guishing peaks on SELDI-TOF MS that correlated with the radiologic stages of the disease. After reverse-phase fractionation, peptide fingerprint mapping, and immunodepletion, a novel protocadherin-2 precursor was identified in the context of the sarcoidosis proteome.
The potential clinical utilities of such an approach are clear. Refinement of the characterization of the sarcoid proteome is likely to help to identify molecules expressed in different phases of the disease, which might, at least in theory, represent putative molecular targets. Furthermore, a proteomic profile could be designed for the clinical evaluation of patients with sarcoidosis. As protein expression data become available, the integration of this technology into protocols for disease diagnosis as well as outcome prediction should soon take place in sarcoidosis. Finally, the application of proteomics could be used in verifying the in vitro effect of molecules, a crucial step in the development of therapeutics. For instance, levels of immunosuppressive or immunomodulatory molecules could be measured directly from a tissue biopsy to assess adequacy of drug delivery to a particular organ site involved by the sarcoid process.
Beyond its clinical implications, proteomic approaches might yield novel information about the pathophysiology of the disease. For example, using SELDI-TOF MS, a number of differences in protein patterns have been demonstrated between alveolar macrophages (AMs) and their precursors or among AMs under different pathologic conditions (7) . Characterization of macrophage-derived and Th1-derived proteins during sarcoidosis will offer a better understanding of its pathogenesis. Lasercapture microdissection permits the isolation of single cells or single populations of cells from thin tissue sections. In combination with SELDI-TOF MS, laser-capture microdissection promises to permit the collection of protein signatures from a single cell type within a heterogeneous sample obtained from a tissue involved by sarcoidosis (8) . This information could significantly improve the understanding of molecular mechanisms underpinning granuloma formation and impact diagnostic pathology of the disease.
It is easy to anticipate that within 5 years the clinical application of proteomic-based techniques will have transformed our knowledge of most physiologic and pathologic pulmonary processes, including sarcoidosis. To use such methodology on a routine basis for a protein-based evaluation of patients with sarcoidosis, the clinical sensitivity and specificity of protein profiling of BAL should be validated by different groups. Of note, comparative analyses of proteomic data obtained from biofluids highlighted important discrepancies in the final results among laboratories, mostly due to the absence of standardized sample collection and processing, and in the use of different pre-and postanalytic strategies (9, 10) . For these reasons, the international scientific community is adopting standardized protocols, which include the use of pooled reference standard samples applied on each protein array and standardized daily calibrations of the instruments, as the minimal essential conditions to validate the data produced by SELDI. There is also a clear need to develop international standards for archiving data obtained from the analysis of lung samples. The validation of standardized The sample is applied to the surface of the chip. As described in the text, the sample is subjected to laser desorption ionization and the formed ions are measured using a time-offlight mass analyzer SELDI-TOF MS methodologies will perhaps require months or years of cooperative effort by the groups involved, but the result will be a rich source of information to aid the physician in patient management.
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Who Are the Children with Asthma Most Susceptible to Air Pollution?
In this issue of the AJRCCM (pp. 1098-1105), Rabinovitch and colleagues (1) show a positive association between fine-particulate air pollution and a biomarker of airway inflammation, urinary leukotriene E 4 (LTE 4 ), in 73 schoolchildren with asthma. LTE 4 is a stable product of the cysteinyl leukotrienes C4 and D4, which are produced by inflammatory cells, including eosinophils, and have bronchoconstrictive and proinflammatory properties. Specifically, the authors of this article found that urinary LTE 4 was associated with morning hourly ambient exposure to particulate matter of less than 2.5 m/m 3 in aerodynamic diameter (PM 2.5 ). They also found that as-needed bronchodilator use at school increased in relation to morning PM 2.5 . LTE 4 was not significantly associated with 24-hour average PM 2.5 . Daily peaks in PM 2.5 occurred in the morning, suggesting that both proximity of exposure measurement to the biomarker measurement as well as peak exposure were important. The availability of hourly PM 2.5
